JAK/STAT signalling pathway in colorectal cancer: A new biological target with therapeutic implications

European Journal of Cancer

Volumn 42, Issue 16, 2006, Pages 2668-2670

  Spano, Jean Philippe ^a   Milano, Gerard ^b   Rixe, Clivier ^a   Fagard, Remi ^c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; ERYTHROPOIETIN; GLYCOPROTEIN GP 130; INTERFERON; JANUS KINASE; PLATELET DERIVED GROWTH FACTOR; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOGENESIS; COLORECTAL CANCER; DIMERIZATION; DNA RESPONSIVE ELEMENT; HUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 33750060073     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.07.006     Document Type: Note

References (27)

1. Schindler C., and Strehlow I. Cytokines and STAT signaling. Adv Pharmacol 47 (2000) 113-174
2. Kisseleva T., Bhattacharya S., Braunstein J., and Schindler C.W. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285 (2002) 1-24
3. Schindler C.W. JAK-STAT signaling in human disease. J Clin Invest 109 (2002) 1133-1137
4. Ceresa B.P., Horvath C.M., and Pessin J.E. Signal transducer and activator of transcription-3 serine phosphorylation by insulin are mediated by a Ras/Raf/Mek-dependant pathway. Endocrinology 138 (1997) 4131-4137
5. Darnell J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
6. Tenev T., Bohmer S.A., Kaufmann R., et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur J Cell Biol 79 (2000) 261-271
7. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8 (2002) 945-954
8. Starr R., and Hilton D.J. Negative regulation of the JAK/STAT pathway. Bioessays 21 (1999) 47-52
9. Chung C.D., Liao J., Liu B., et al. Specific inhibition of STAT3 signal transduction by PIAS3. Science 278 (1997) 1803-1805
10. Park O.K., Schaefer T.S., and Nathans D. In vitro activation of Stat3 by epidermal growth factor receptor kinase. Proc Natl Acad Sci 93 (1996) 13704-13708
11. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
12. Shao H., Cheng H.Y., Cook R.G., and Tweardy D.J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res 63 (2003) 3923-3930
13. Berclaz G., Altermatt H.J., Rohrbach V., et al. EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncology 19 (2001) 1155-1160
14. Hinz M., Lemke P., Anagnostopoulos I., et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 196 (2002) 605-617
15. Kelly J.A., Spolski R., Kovanen P.E., et al. STAT5 synergises with T cell receptor/antigen stimulation in the development of lymphoblastic lymphoma. J Exp Med 198 (2003) 79-89
16. Schwaller J., Parganas E., Wang D., et al. STAT5 is essential for the myelo-and lymphoproliferative disease induced by TEL/JAK2. Mol Cell 6 (2000) 693-704
17. Maurer A.B., Wichmann C., Gross A., et al. The STAT5-RARalpha fusion protein represses transcription and differenciation through interaction with a corepressor complex. Blood 99 (2002) 2647-2652
18. Gouilleux-Gruart V., Gouilleux F., Desaint C., et al. STAT-related transcription factors are constituvely activated in peripheral blood cells from acute leukemia patients. Blood 87 (1996) 1692-1697
19. Ma X.T., Wang S., Ye Y.J., et al. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 10 (2004) 1569-1573
20. Corvinus F.M., Orth C., Moriggl R., et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 7 (2005) 545-555
21. Tadlaoui Hbibi A, Lagorce C, Spano JP, et al. Detection of tyrosine 416-phosphorylated p60c-src in a series of colorectal carcinoma correlates with high expression of the EGFR and phosphorylation of STAT3 on tyrosine 705. submitted for publication.
22. Spano J.P., Lagorce C., Atlan D., et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16 (2005) 102-108
23. Garcia R., Bowman T.L., Niu G., et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20 (2000) 2499-2513
24. Niu G., Heller R., Catlett-Falcone R., et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 59 (1999) 5059-5063
25. Turkson J., Ryan D., Kim J.S., et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation and cell transformation. J Biol Chem 276 (2001) 45443-45455
26. Dowlati A., Nethery D., and Kern J.A. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther 3 (2004) 459-463
27. Leeman R.J., Lui V.W., and Grandis J.R. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6 (2006) 231-241